resource Library


WATCH videos from experts, and explore future EVENTS.

Watch and Learn More About DUPIXENT


[DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.]

Let’s go through a hypothetical case. Let’s go through this case of a 52-year old female with adult-onset asthma who’s frequently on oral corticosteroids. Every time that we’ve tried to take her off oral corticosteroids it’s led to worsening of symptoms and also another exacerbation. She definitely wants to stop oral corticosteroids because of weight gain, but she fears having another exacerbation. Because of her asthma, she avoids social activities due to other symptoms and like a lot of asthmatics that we actually see, she also reports that she’s got nasal polyps. [Patient profile is representative and is not an actual DUPIXENT patient.] Other information that is important to know is that she’s had two severe exacerbations in the past year, she’s got poor lung function with an FEV1 of 58%, she was diagnosed with asthma at the age of 23 with nasal polyps at age 38, and her asthma is still uncontrolled with an ACT score of 15 despite being on maximum inhaled corticosteroids, long acting beta agonist and also leukotriene receptor antagonist. She’s had multiple courses of oral corticosteroids over the last 6 months and she continues to use nasal irrigation along with intranasal corticosteroids for nasal polyps. And even then, you can see that she’s not exactly doing well. Biomarkers that was actually done blood eosinophils of 140 with a total serum IgE of 405. So when we look at her we realize that because she is oral corticosteroid dependent, this would definitely be a patient that we would want to consider putting on DUPIXENT. In addition to that even despite her eosinophils being 140 because she’s OCS dependent, that is something to think about as to why she would actually benefit from DUPIXENT.


The mechanism of action for DUPIXENT is unique. It is the only fully human IgG-4 monoclonal antibody that binds to Interleuken-4 receptor alpha. And we can say it’s the subunit shared by IL-4 and IL-13 receptors. As you can see in the picture in the diagram, Type 1 receptor has an IL-4 receptor alpha and also a gamma chain subunit. How is that different from a Type II receptor? Well for Type II receptors there’s an IL-4 receptor alpha and also at least in the Type II receptor side, an IL-13 receptor alpha 1. Now, in order for self-signaling to occur both of these subunits actually need to come together. And they will come together only when IL-4 actually binds to IL-4 receptor alpha at least in the Type 1 receptor and for Type II IL-4 and IL-13 needs to bind to get to each of the corresponding subunits. DUPIXENT works by binding or blocking also the IL-4 receptor alpha therefore, IL-4 does not have the ability to actually bind on to that specific subunit. [The mechanism of DUPIXENT action in asthma has not been definitively established.] DUPIXENT’s able to decrease multiple biomarkers. Biomarkers that we see commonly in Type 2 inflammation. It’s able to decrease IgE by up to 70% and fractional exhaled nitric oxide of up to 35%. Other biomarkers that are not commercially available currently right now were also decreased like eotaxin-3, TARC, and periostin. [Correlations between DUPIXENT pharmocodynamics data and efficacy endpoints have not been established]

Type 2 inflammation occurs in up to 50% to 84% of adult patients with asthma and plays an important role in the pathogenesis of asthma.

The Type 2 inflammatory pathway encompasses both allergic and eosinophilic inflammation.

Disruption of airway epithelium barrier functions along with allergen uptake by dendritic cells and activation of T cells help drive Type 2 inflammation in asthma. There are multiple cell types and mediators involved in Type 2 inflammation—including IL-4 and IL-13. IL-4 drives Th2 cell differentiation and mediates the production of Type 2 cytokines.

IL-4 and IL-13 play an important role in class switching of B cells to produce IgE, a key component of allergic inflammation.

IL-13 mediates goblet cell hyperplasia and increased mucus secretion and promotes airway obstruction, bronchial hyperreactivity, smooth muscle hypertrophy, airway remodeling, and stimulation of nitric oxide synthase to produce nitric oxide.

IL-4 and IL-13 drive the trafficking of eosinophils to sites of inflammation and IL-5 mediates the differentiation of eosinophils in bone marrow, which contributes to eosinophilic inflammation.

IL-4 and IL-13 are two key cytokines that contribute to allergic and eosinophilic inflammation.

DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling, impacting two of the sources that mediate allergic and eosinophilic inflammation.

[The mechanism of dupilumab action in asthma has not been definitively established.]

In the inflammatory process, IL-4 binds the IL-4Rα subunit, and IL-13 binds the IL-13Rα1 subunit, which is the same as the IL-4Rα subunit.

DUPIXENT binds to IL-4Rα, blocking IL-4 and IL-13 intracellular signaling; this results in reduced expression of proinflammatory cytokines, ultimately leading to decreased total and specific IgE, decreased FeNO, and a transient increase in blood eosinophils.

DUPIXENT blocks the IL-4/IL-13 pathway and decreases markers of Type 2 inflammation, including IgE, in which there was up to 70% reduction in total IgE from baseline and a reduction in eosinophilic lung inflammation, despite the presence of normal or increased blood eosinophil levels. DUPIXENT also reduced levels of FeNO by blocking IL-13, which is responsible for stimulating nitric oxide synthase to produce nitric oxide.

Based on a study of the general asthma population approximately 7 out of 10 asthma patients had an eosinophilic phenotype or an overlap of eosinophilic and allergic phenotypes.

DUPIXENT is indicated for patients (12 plus years) with moderate-to-severe asthma with an eosinophilic phenotype and is the only biologic indicated for an OCS-dependent asthma population, regardless of phenotype.

DUPIXENT is a novel biologic that inhibits IL-4 and IL-13 signaling, two of the sources of inflammation in asthma.

Download and Discover More About DUPIXENT


Explore the OCS-dependent
patient type and clinical



Take a look at the MOA and
efficacy and safety data for



This tool can help provide
an overview for your patients
prescribed DUPIXENT


Join Us at Virtual Educational Events for DUPIXENT in 2021

Explore Dupixent Like Never Before

Tour the DUPIXENT virtual booth to learn more information about this biologic, including appropriate patient types, its MOA, efficacy and safety data, and how to help your appropriate patients start and stay on DUPIXENT.


Mark Your Calendars for These Future Events

CHEST 2021
October 2021

American College of
Allergy, Asthma &
Immunology (ACAAI) 2021

November 2021

AAAAI Annual
Meeting 2022

February 2022

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

Learn how we can help

DUPIXENT MyWay Enrollment Forms:





Important Safety
Information and Indication

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.


Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Physicians should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult patients who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult patients who participated in the asthma development program as well as in adult patients with co-morbid asthma in the chronic rhinosinusitis with nasal polyposis development program. A causal association between DUPIXENT and these conditions has not been established.

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1%) in patients with asthma are injection site reactions, oropharyngeal pain, and eosinophilia.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.


  • Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Healthcare providers and patients may call 1-877-311-8972 or go to to enroll in or obtain information about the registry. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.


DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.